Circulation. 2005;112:1756-1762
Published online before print September 12, 2005, doi: 10.1161/CIRCULATIONAHA.104.530972
Published online before print September 12, 2005, doi: 10.1161/CIRCULATIONAHA.104.530972
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:1756-1762.)
© 2005 American Heart Association, Inc.
Heart Failure |
Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure
From the Department of Cardiology and Endocrinology, Frederiksberg University Hospital (C.K., P.H.), Copenhagen, Denmark; Department of Endocrinology, Herlev University Hospital (J. Faber), Copenhagen, Denmark; Department of Cardiology, Gentofte University Hospital (S.G.), Gentofte, Denmark; Department of Cardiology, State University Hospital (Rigshospitalet) (F.G.), Copenhagen, Denmark; and Medical Research Laboratories, Medical Department (Diabetes and Endocrinology), Aarhus University Hospital (J. Frystyk, A.F.), Aarhus, Denmark.
Correspondence to Caroline Kistorp, MD, Department of Cardiology and Endocrinology, Frederiksberg University Hospital, 57 Nordre Fasanvej, DK-2000 Frederiksberg, Denmark. E-mail cnkistorp{at}dadlnet.dk
Received December 20, 2004; revision received June 1, 2005; accepted June 24, 2005.
Background— Recent studies have suggested that higher body mass index (BMI) is associated with improved prognosis in chronic heart failure (CHF). The adipocytokine adiponectin is inversely associated with BMI, and in healthy subjects, low adiponectin is a predictor of mortality. In a prospective study, we therefore evaluated the association between plasma adiponectin levels and mortality among patients with CHF.
Methods and Results— In 195 CHF patients (age 69.3±10.2 years, BMI 27.3±5.2 kg/m2, left ventricular ejection fraction 30±8.9%, mean±SD), plasma adiponectin and N-terminal pro brain natriuretic peptide (NT-proBNP) were measured at baseline. Adiponectin was positively associated with NT-proBNP (ß=0.47, P<0.001), and both biomarkers were negatively associated with BMI (ß=–0.43, P<0.001 for adiponectin and ß=–0.38, P<0.001 for NT-proBNP, respectively) During a median follow-up of 2.6 years, 46 (23.5%) of the patients died. After adjustment for clinical variables associated with CHF severity (age, systolic blood pressure, left ventricular ejection fraction <25%, duration of CHF, and creatinine clearance) and for NT-proBNP, the hazard ratio of mortality for values in the 2 upper tertiles relative to the lowest tertile of adiponectin was 3.23 (P=0.032). BMI predicted mortality independently of clinical parameters of CHF severity (hazard ratio=0.63, P=0.012), but this association became insignificant after additional adjustment for NT-proBNP (hazard ratio=0.74, P=0.13).
Conclusions— A high adiponectin level was a predictor of mortality, independent of risk markers of CHF severity, presumably because of its role as a marker for wasting. BMI was also associated with mortality, but a part of this relation may be mediated by adiponectin and NT-proBNP levels.
Key Words: adiponectin • body mass index • natriuretic peptides • heart failure
This article has been cited by other articles:
 |
|
 |
|
  T. Tsutamoto, M. Yamaji, C. Kawahara, K. Nishiyama, M. Fujii, T. Yamamoto, and M. Horie Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure Eur J Heart Fail, December 1, 2009; 11(12): 1195 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Esteve, W. Ricart, and J. M. Fernandez-Real Adipocytokines and Insulin Resistance: The possible role of lipocalin-2, retinol binding protein-4, and adiponectin Diabetes Care, November 1, 2009; 32(suppl_2): S362 - S367. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tsukamoto, M. Fujita, M. Kato, S. Yamazaki, Y. Asano, A. Ogai, H. Okazaki, M. Asai, Y. Nagamachi, N. Maeda, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2070 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Costello-Boerrigter and J. C. Burnett Jr A new role for the natriuretic peptides metabolic regulators of the adipocyte. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2078 - 2079. [Full Text] [PDF]
|
|
|
|
|
|
J. Paulo Araujo, P. Lourenco, F. Rocha-Goncalves, A. Ferreira, and P. Bettencourt Adiponectin is increased in cardiac cachexia irrespective of body mass index Eur J Heart Fail, June 1, 2009; 11(6): 567 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Higuchi, K. Ohashi, S. Kihara, K. Walsh, and N. Ouchi Adiponectin Suppresses Pathological Microvessel Formation in Retina Through Modulation of Tumor Necrosis Factor-{alpha} Expression Circ. Res., May 8, 2009; 104(9): 1058 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Frankel, R. S. Vasan, R. B. D'Agostino Sr, E. J. Benjamin, D. Levy, T. J. Wang, and J. B. Meigs Resistin, Adiponectin, and Risk of Heart Failure: The Framingham Offspring Study J. Am. Coll. Cardiol., March 3, 2009; 53(9): 754 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M B Snijder, A Flyvbjerg, C D A Stehouwer, J Frystyk, R M A Henry, J C Seidell, R J Heine, and J M Dekker Relationship of adiposity with arterial stiffness as mediated by adiponectin in older men and women: the Hoorn Study Eur. J. Endocrinol., March 1, 2009; 160(3): 387 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ingelsson, J. Arnlov, B. Zethelius, R. S. Vasan, A. Flyvbjerg, J. Frystyk, C. Berne, A. Hanni, L. Lind, and J. Sundstrom Associations of Serum Adiponectin with Skeletal Muscle Morphology and Insulin Sensitivity J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 953 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B Schnabel and S. Blankenberg Commentary: Circulating cytokines and risk stratification of stroke incidence--will we do better in future? Int. J. Epidemiol., February 1, 2009; 38(1): 261 - 262. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ashrafian, C. W. le Roux, A. Darzi, and T. Athanasiou Effects of Bariatric Surgery on Cardiovascular Function Circulation, November 11, 2008; 118(20): 2091 - 2102. [Full Text] [PDF]
|
|
|
|
 |
|
 M. von Eynatten, H. Brenner, and D. Rothenbacher Adiponectin and prognostic outcome in patients with coronary artery disease: reply Eur. Heart J., October 2, 2008; 29(20): 2579 - 2580. [Full Text] [PDF]
|
|
|
|
|
|
N. Sattar and S. M. Nelson Adiponectin, Diabetes, and Coronary Heart Disease in Older Persons: Unraveling the Paradox J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3299 - 3301. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Kizer, J. I. Barzilay, L. H. Kuller, and J. S. Gottdiener Adiponectin and Risk of Coronary Heart Disease in Older Men and Women J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3357 - 3364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Maiolino, M. Cesari, D. Sticchi, M. Zanchetta, L. Pedon, K. Antezza, A. C. Pessina, and G. P. Rossi Plasma Adiponectin for Prediction of Cardiovascular Events and Mortality in High-Risk Patients J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3333 - 3340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rao, L. Li, H. Tighiouart, B. L. Jaber, B. J. G. Pereira, V. S. Balakrishnan, and the HEMO Study Group Plasma adiponectin levels and clinical outcomes among haemodialysis patients Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2619 - 2628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Leth, K. K. Andersen, J. Frystyk, L. Tarnow, P. Rossing, H.-H. Parving, and A. Flyvbjerg Elevated Levels of High-Molecular-Weight Adiponectin in Type 1 Diabetes J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3186 - 3191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schnabel Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study: reply Eur. Heart J., August 1, 2008; 29(15): 1923 - 1924. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Karmazyn, D. M. Purdham, V. Rajapurohitam, and A. Zeidan Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart Cardiovasc Res, July 15, 2008; 79(2): 279 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Braunwald Biomarkers in Heart Failure N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159. [Full Text] [PDF]
|
|
|
|
|
|
C. Skurk, F. Wittchen, L. Suckau, H. Witt, M. Noutsias, H. Fechner, H.-P. Schultheiss, and W. Poller Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy Eur. Heart J., May 1, 2008; 29(9): 1168 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Abel, S. E. Litwin, and G. Sweeney Cardiac Remodeling in Obesity Physiol Rev, April 1, 2008; 88(2): 389 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C. D. A. Stehouwer, M. B. Snijder, L. M. Bouter, Y. Matsuzawa, I. Shimomura, and R. J. Heine Prognostic Value of Adiponectin for Cardiovascular Disease and Mortality J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1489 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanaka, T. Tsutamoto, H. Sakai, K. Nishiyama, M. Fujii, T. Yamamoto, and M. Horie Effect of atrial natriuretic peptide on adiponectin in patients with heart failure Eur J Heart Fail, April 1, 2008; 10(4): 360 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kistorp, A. Y. Chong, F. Gustafsson, S. Galatius, I. Raymond, J. Faber, G. Y.H. Lip, and P. Hildebrandt Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes Eur J Heart Fail, April 1, 2008; 10(4): 380 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.C. Astor, S. Yi, L. Hiremath, T. Corbin, V. Pogue, B. Wilkening, G. Peterson, J. Lewis, J.P. Lash, F. Van Lente, et al. N-Terminal Prohormone Brain Natriuretic Peptide as a Predictor of Cardiovascular Disease and Mortality in Blacks With Hypertensive Kidney Disease: The African American Study of Kidney Disease and Hypertension (AASK) Circulation, April 1, 2008; 117(13): 1685 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ybarra, F. Planas, and J. M Pou Aminoterminal pro-brain natriuretic peptide (NT-proBNP) and sleep-disordered breathing in morbidly obese females: a cross-sectional study Diabetes and Vascular Disease Research, March 1, 2008; 5(1): 19 - 24. [Abstract] [PDF]
|
|
|
|
|
|
R. Schnabel, C. M. Messow, E. Lubos, C. Espinola-Klein, H. J. Rupprecht, C. Bickel, C. Sinning, S. Tzikas, T. Keller, S. Genth-Zotz, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study Eur. Heart J., March 1, 2008; 29(5): 649 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle? Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 505 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Carrero, O. Heimburger, P. Stenvinkel, and B. Lindholm Reply to A Molfino et al Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1551 - 1553. [Full Text] [PDF]
|
|
|
|
|
|
G. D. Lopaschuk, C. D.L. Folmes, and W. C. Stanley Cardiac Energy Metabolism in Obesity Circ. Res., August 17, 2007; 101(4): 335 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. von Haehling, T. B. Horwich, G. C. Fonarow, and S. D. Anker Tipping the Scale: Heart Failure, Body Mass Index, and Prognosis Circulation, August 7, 2007; 116(6): 588 - 590. [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Wannamethee, P. H. Whincup, L. Lennon, and N. Sattar Circulating Adiponectin Levels and Mortality in Elderly Men With and Without Cardiovascular Disease and Heart Failure Arch Intern Med, July 23, 2007; 167(14): 1510 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsutamoto, T. Tanaka, H. Sakai, C. Ishikawa, M. Fujii, T. Yamamoto, and M. Horie Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure Eur. Heart J., July 2, 2007; 28(14): 1723 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kintscher Does adiponectin resistance exist in chronic heart failure? Eur. Heart J., July 2, 2007; 28(14): 1676 - 1677. [Full Text] [PDF]
|
|
|
|
|
|
M. B. McEntegart, B. Awede, M. C. Petrie, N. Sattar, F. G. Dunn, N. G. MacFarlane, and J. J.V. McMurray Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide Eur. Heart J., April 2, 2007; (2007) ehm033v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko, H. Teoh, D. J. Stewart, and S. Verma Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1655 - H1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Hopkins, N. Ouchi, R. Shibata, and K. Walsh Adiponectin actions in the cardiovascular system Cardiovasc Res, April 1, 2007; 74(1): 11 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Wang, M. G. Larson, M. J. Keyes, D. Levy, E. J. Benjamin, and R. S. Vasan Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals Circulation, March 20, 2007; 115(11): 1345 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bayes-Genis, D. M. Lloyd-Jones, R. R. J. van Kimmenade, J. G. Lainchbury, A. M. Richards, J. Ordonez-Llanos, M. Santalo, Y. M. Pinto, and J. L. Januzzi Jr Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro-Brain Natriuretic Peptide in Patients With Acute Dyspnea Arch Intern Med, February 26, 2007; 167(4): 400 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pilz, H. Mangge, B. Wellnitz, U. Seelhorst, B. R. Winkelmann, B. Tiran, B. O. Boehm, and W. Marz Adiponectin and Mortality in Patients Undergoing Coronary Angiography J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4277 - 4286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cavusoglu, C. Ruwende, V. Chopra, S. Yanamadala, C. Eng, L. T. Clark, D. J. Pinsky, and J. D. Marmur Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain Eur. Heart J., October 1, 2006; 27(19): 2300 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Teoh, M. H. Strauss, P. E. Szmitko, and S. Verma Adiponectin and myocardial infarction: a paradox or a paradigm? Eur. Heart J., October 1, 2006; 27(19): 2266 - 2268. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Menon, L. Li, X. Wang, T. Greene, V. Balakrishnan, M. Madero, A. A. Pereira, G. J. Beck, J. W. Kusek, A. J. Collins, et al. Adiponectin and Mortality in Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2599 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pischon and E. B. Rimm Adiponectin: a promising marker for cardiovascular disease. Clin. Chem., May 1, 2006; 52(5): 797 - 799. [Full Text] [PDF]
|
|
|
|
|
|
M. von Eynatten, A. Hamann, D. Twardella, P. P. Nawroth, H. Brenner, and D. Rothenbacher Relationship of Adiponectin with Markers of Systemic Inflammation, Atherogenic Dyslipidemia, and Heart Failure in Patients with Coronary Heart Disease Clin. Chem., May 1, 2006; 52(5): 853 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ingelsson, U. Riserus, C. Berne, J. Frystyk, A. Flyvbjerg, T. Axelsson, P. Lundmark, and B. Zethelius Adiponectin and risk of congestive heart failure. JAMA, April 19, 2006; 295(15): 1772 - 1774. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Touyz Endothelial Cell IL-8, a New Target for Adiponectin: Implications in Vascular Protection Circ. Res., December 9, 2005; 97(12): 1216 - 1219. [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2125 - 2133. [Full Text] [PDF]
|
|